<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20240904161121&amp;utm_campaign=pubmed-2&amp;utm_medium=rss&amp;fc=20230708114047&amp;utm_source=Chrome&amp;v=2.18.0.post9+e462414
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20240904161121&amp;utm_campaign=pubmed-2&amp;utm_medium=rss&amp;fc=20230708114047&amp;utm_source=Chrome&amp;v=2.18.0.post9+e462414" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Wed, 04 Sep 2024 20:11:22 +0000</lastbuilddate>
<pubDate>Wed, 04 Sep 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Sudden Hemodynamic Deterioration of a 75-Year-Old Woman With Progressive Jaw Pain</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39230916/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240904161121&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Sep 4. doi: 10.1001/jamacardio.2024.2695. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39230916/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240904161121&v=2.18.0.post9+e462414">39230916</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.2695>10.1001/jamacardio.2024.2695</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39230916</guid>
<pubDate>Wed, 04 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Sven L Van Laer</dc:creator>
<dc:creator>Pieterjan Van Rijckeghem</dc:creator>
<dc:creator>Vincent F M Segers</dc:creator>
<dc:date>2024-09-04</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Sudden Hemodynamic Deterioration of a 75-Year-Old Woman With Progressive Jaw Pain</dc:title>
<dc:identifier>pmid:39230916</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.2695</dc:identifier>
</item>
<item>
<title>Addressing Evidence Gaps in Coronary Revascularization Trials</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39230898/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240904161121&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Sep 4. doi: 10.1001/jamacardio.2024.2778. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39230898/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240904161121&v=2.18.0.post9+e462414">39230898</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.2778>10.1001/jamacardio.2024.2778</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39230898</guid>
<pubDate>Wed, 04 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Gregg W Stone</dc:creator>
<dc:creator>Clyde W Yancy</dc:creator>
<dc:creator>Mario Gaudino</dc:creator>
<dc:date>2024-09-04</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Addressing Evidence Gaps in Coronary Revascularization Trials</dc:title>
<dc:identifier>pmid:39230898</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.2778</dc:identifier>
</item>
<item>
<title>Genome-Wide Association Study of Accessory Atrioventricular Pathways</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39230897/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240904161121&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: Associations were found between sequence variants and APs that were also associated with risk of PSVT, and thus likely atrioventricular reentrant tachycardia, but had allele-specific associations with AF and conduction disorders. Genetic variation in the modulation of heart rate, chronotropic response, and atrial or atrioventricular node conduction velocity may play a role in the risk of AP-affiliated arrhythmias. Further research into CCDC141 could provide insights...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Sep 4. doi: 10.1001/jamacardio.2024.2684. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Understanding of the genetics of accessory atrioventricular pathways (APs) and affiliated arrhythmias is limited.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To investigate the genetics of APs and affiliated arrhythmias.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This was a genome-wide association study (GWAS) of APs, defined by International Classification of Diseases (ICD) codes and/or confirmed by electrophysiology (EP) study. Genome-wide significant AP variants were tested for association with AP-affiliated arrhythmias: paroxysmal supraventricular tachycardia (PSVT), atrial fibrillation (AF), ventricular tachycardia, and cardiac arrest. AP variants were also tested in data on other heart diseases and measures of cardiac physiology. Individuals with APs and control individuals from Iceland (deCODE Genetics), Denmark (Copenhagen Hospital Biobank, Danish Blood Donor Study, and SupraGen/the Danish General Suburban Population Study [GESUS]), the US (Intermountain Healthcare), and the United Kingdom (UK Biobank) were included. Time of phenotype data collection ranged from January 1983 to December 2022. Data were analyzed from August 2022 to January 2024.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURES: Sequence variants.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Genome-wide significant association of sequence variants with APs.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The GWAS included 2310 individuals with APs (median [IQR] age, 43 [28-57] years; 1252 [54.2%] male and 1058 [45.8%] female) and 1 206 977 control individuals (median [IQR] year of birth, 1955 [1945-1970]; 632 888 [52.4%] female and 574 089 [47.6%] male). Of the individuals with APs, 909 had been confirmed in EP study. Three common missense variants were associated with APs, in the genes CCDC141 (p.Arg935Trp: adjusted odds ratio [aOR], 1.37; 95% CI, 1.24-1.52, and p.Ala141Val: aOR, 1.55; 95% CI 1.34-1.80) and SCN10A (p.Ala1073Val: OR, 1.22; 95% CI, 1.15-1.30). The 3 variants associated with PSVT and the SCN10A variant associated with AF, supporting an effect on AP-affiliated arrhythmias. All 3 AP risk alleles were associated with higher heart rate and shorter PR interval, and have reported associations with chronotropic response.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Associations were found between sequence variants and APs that were also associated with risk of PSVT, and thus likely atrioventricular reentrant tachycardia, but had allele-specific associations with AF and conduction disorders. Genetic variation in the modulation of heart rate, chronotropic response, and atrial or atrioventricular node conduction velocity may play a role in the risk of AP-affiliated arrhythmias. Further research into CCDC141 could provide insights for antiarrhythmic therapeutic targeting in the presence of an AP.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39230897/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240904161121&v=2.18.0.post9+e462414">39230897</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.2684>10.1001/jamacardio.2024.2684</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39230897</guid>
<pubDate>Wed, 04 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Hildur M Aegisdottir</dc:creator>
<dc:creator>Laura Andreasen</dc:creator>
<dc:creator>Rosa B Thorolfsdottir</dc:creator>
<dc:creator>Gardar Sveinbjornsson</dc:creator>
<dc:creator>Andrea B Jonsdottir</dc:creator>
<dc:creator>Lilja Stefansdottir</dc:creator>
<dc:creator>Gudmar Thorleifsson</dc:creator>
<dc:creator>Asgeir Sigurdsson</dc:creator>
<dc:creator>Gisli H Halldorsson</dc:creator>
<dc:creator>Julien Barc</dc:creator>
<dc:creator>Floriane Simonet</dc:creator>
<dc:creator>Vinicius Tragante</dc:creator>
<dc:creator>Asmundur Oddsson</dc:creator>
<dc:creator>Egil Ferkingstad</dc:creator>
<dc:creator>Jesper Hastrup Svendsen</dc:creator>
<dc:creator>Jonas Ghouse</dc:creator>
<dc:creator>Gustav Ahlberg</dc:creator>
<dc:creator>Christian Paludan-Müller</dc:creator>
<dc:creator>Katra Hadji-Turdeghal</dc:creator>
<dc:creator>Mariana Bustamante</dc:creator>
<dc:creator>Magnus O Ulfarsson</dc:creator>
<dc:creator>Anna Helgadottir</dc:creator>
<dc:creator>Solveig Gretarsdottir</dc:creator>
<dc:creator>Saedis Saevarsdottir</dc:creator>
<dc:creator>Ingileif Jonsdottir</dc:creator>
<dc:creator>Christian Erikstrup</dc:creator>
<dc:creator>Henrik Ullum</dc:creator>
<dc:creator>Erik Sørensen</dc:creator>
<dc:creator>Søren Brunak</dc:creator>
<dc:creator>Christian Jøns</dc:creator>
<dc:creator>Chaoqun Zheng</dc:creator>
<dc:creator>Connie R Bezzina</dc:creator>
<dc:creator>Kirk U Knowlton</dc:creator>
<dc:creator>Lincoln D Nadauld</dc:creator>
<dc:creator>Patrick Sulem</dc:creator>
<dc:creator>Sisse R Ostrowski</dc:creator>
<dc:creator>Ole B Pedersen</dc:creator>
<dc:creator>David O Arnar</dc:creator>
<dc:creator>Daniel F Gudbjartsson</dc:creator>
<dc:creator>Morten S Olesen</dc:creator>
<dc:creator>Henning Bundgaard</dc:creator>
<dc:creator>Hilma Holm</dc:creator>
<dc:creator>Kari Stefansson</dc:creator>
<dc:creator>DBDS consortium</dc:creator>
<dc:date>2024-09-04</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Genome-Wide Association Study of Accessory Atrioventricular Pathways</dc:title>
<dc:identifier>pmid:39230897</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.2684</dc:identifier>
</item>
<item>
<title>Aficamten and Cardiopulmonary Exercise Test Performance: A Substudy of the SEQUOIA-HCM Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39230885/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240904161121&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: This prespecified analysis of the SEQUOIA-HCM randomized clinical trial found that aficamten treatment improved a broad range of exercise performance measures. These findings offer valuable insight into the therapeutic effects of aficamten.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Sep 4. doi: 10.1001/jamacardio.2024.2781. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Impaired exercise capacity is a cardinal manifestation of obstructive hypertrophic cardiomyopathy (HCM). The Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Obstructive HCM (SEQUOIA-HCM) is a pivotal study characterizing the treatment effect of aficamten, a next-in-class cardiac myosin inhibitor, on a comprehensive set of exercise performance and clinical measures.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To evaluate the effect of aficamten on exercise performance using cardiopulmonary exercise testing with a novel integrated measure of maximal and submaximal exercise performance and evaluate other exercise measures and clinical correlates.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This was a prespecified analysis from SEQUOIA-HCM, a double-blind, placebo-controlled, randomized clinical trial. Patients were recruited from 101 sites in 14 countries (North America, Europe, Israel, and China). Individuals with symptomatic obstructive HCM with objective exertional intolerance (peak oxygen uptake [pVO2] ≤90% predicted) were included in the analysis. Data were analyzed from January to March 2024.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTIONS: Randomized 1:1 to aficamten (5-20 mg daily) or matching placebo for 24 weeks.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The primary outcome was change from baseline to week 24 in integrated exercise performance, defined as the 2-component z score of pVO2 and ventilatory efficiency throughout exercise (minute ventilation [VE]/carbon dioxide output [VCO2] slope). Response rates for achieving clinically meaningful thresholds for change in pVO2 and correlations with clinical measures of treatment effect (health status, echocardiographic/cardiac biomarkers) were also assessed.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 282 randomized patients (mean [SD] age, 59.1 [12.9] years; 115 female [40.8%], 167 male [59.2%]), 263 (93.3%) had core laboratory-validated exercise testing at baseline and week 24. Integrated composite exercise performance improved in the aficamten group (mean [SD] z score, 0.17 [0.51]) from baseline to week 24, whereas the placebo group deteriorated (mean [SD] z score, -0.19 [0.45]), yielding a placebo-corrected improvement of 0.35 (95% CI, 0.25-0.46; P &lt;.001). Further, aficamten treatment demonstrated significant improvements in total workload, circulatory power, exercise duration, heart rate reserve, peak heart rate, ventilatory efficiency, ventilatory power, and anaerobic threshold (all P &lt;.001). In the aficamten group, large improvements (≥3.0 mL/kg per minute) in pVO2 were more common than large reductions (32% and 2%, respectively) compared with placebo (16% and 11%, respectively). Improvements in both components of the primary outcome, pVO2 and VE/VCO2 slope throughout exercise, were significantly correlated with improvements in symptom burden and hemodynamics (all P &lt;.05).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: This prespecified analysis of the SEQUOIA-HCM randomized clinical trial found that aficamten treatment improved a broad range of exercise performance measures. These findings offer valuable insight into the therapeutic effects of aficamten.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05186818.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39230885/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240904161121&v=2.18.0.post9+e462414">39230885</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.2781>10.1001/jamacardio.2024.2781</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39230885</guid>
<pubDate>Wed, 04 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Matthew M Y Lee</dc:creator>
<dc:creator>Ahmad Masri</dc:creator>
<dc:creator>Michael E Nassif</dc:creator>
<dc:creator>Roberto Barriales-Villa</dc:creator>
<dc:creator>Theodore P Abraham</dc:creator>
<dc:creator>Brian L Claggett</dc:creator>
<dc:creator>Caroline J Coats</dc:creator>
<dc:creator>Juan Ramón Gimeno</dc:creator>
<dc:creator>Ian J Kulac</dc:creator>
<dc:creator>Isabela Landsteiner</dc:creator>
<dc:creator>Changsheng Ma</dc:creator>
<dc:creator>Martin S Maron</dc:creator>
<dc:creator>Iacopo Olivotto</dc:creator>
<dc:creator>Anjali T Owens</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:creator>Josef Veselka</dc:creator>
<dc:creator>Daniel L Jacoby</dc:creator>
<dc:creator>Stephen B Heitner</dc:creator>
<dc:creator>Stuart Kupfer</dc:creator>
<dc:creator>Fady I Malik</dc:creator>
<dc:creator>Lisa Meng</dc:creator>
<dc:creator>Amy Wohltman</dc:creator>
<dc:creator>Gregory D Lewis</dc:creator>
<dc:creator>SEQUOIA-HCM Investigators</dc:creator>
<dc:date>2024-09-04</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Aficamten and Cardiopulmonary Exercise Test Performance: A Substudy of the SEQUOIA-HCM Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:39230885</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.2781</dc:identifier>
</item>
<item>
<title>Short-Term Effects of Lower Air Temperature and Cold Spells on Myocardial Infarction Hospitalizations in Sweden</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39230547/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240904161121&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: This nationwide case-crossover study reveals that short-term exposures to lower air temperature and cold spells are associated with an increased risk of hospitalization for MI at lag 2 to 6 days.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 19:S0735-1097(24)07842-2. doi: 10.1016/j.jacc.2024.07.006. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Lower air temperature and cold spells have been associated with an increased risk of various diseases. However, the short-term effect of lower air temperature and cold spells on myocardial infarction (MI) remains incompletely understood.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The purpose of this study was to investigate the short-term effects of lower air temperature and cold spells on the risk of hospitalization for MI in Sweden.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This population-based nationwide study included 120,380 MI cases admitted to hospitals in Sweden during the cold season (October to March) from 2005 to 2019. Daily mean air temperature (1 km<sup>2</sup> resolution) was estimated using machine learning, and percentiles of daily temperatures experienced by individuals in the same municipality were used as individual exposure indicators to account for potential geographic adaptation. Cold spells were defined as periods of at least 2 consecutive days with a daily mean temperature below the 10th percentile of the temperature distribution for each municipality. A time-stratified case-crossover design incorporating conditional logistic regression models with distributed lag nonlinear models using lag 0 to 1 (immediate) and 2 to 6 days (delayed) was used to evaluate the short-term effects of lower air temperature and cold spells on total MI, non-ST-segment elevation myocardial infarction (NSTEMI) and ST-segment elevation myocardial infarction (STEMI).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A decrease of 1-unit in percentile temperature at a lag of 2 to 6 days was significantly associated with increased risks of total MI, NSTEMI, and STEMI, with ORs of 1.099 (95% CI: 1.057-1.142), 1.110 (95% CI: 1.060-1.164), and 1.076 (95% CI: 1.004-1.153), respectively. Additionally, cold spells at a lag of 2 to 6 days were significantly associated with increased risks for total MI, NSTEMI, and STEMI, with ORs of 1.077 (95% CI: 1.037-1.120), 1.069 (95% CI: 1.020-1.119), and 1.095 (95% CI: 1.023-1.172), respectively. Conversely, lower air temperature and cold spells at a lag of 0 to 1 days were associated with decreased risks for MI.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: This nationwide case-crossover study reveals that short-term exposures to lower air temperature and cold spells are associated with an increased risk of hospitalization for MI at lag 2 to 6 days.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39230547/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240904161121&v=2.18.0.post9+e462414">39230547</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.07.006>10.1016/j.jacc.2024.07.006</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39230547</guid>
<pubDate>Wed, 04 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Wenli Ni</dc:creator>
<dc:creator>Massimo Stafoggia</dc:creator>
<dc:creator>Siqi Zhang</dc:creator>
<dc:creator>Petter Ljungman</dc:creator>
<dc:creator>Susanne Breitner</dc:creator>
<dc:creator>Jeroen de Bont</dc:creator>
<dc:creator>Tomas Jernberg</dc:creator>
<dc:creator>Dan Atar</dc:creator>
<dc:creator>Stefan Agewall</dc:creator>
<dc:creator>Alexandra Schneider</dc:creator>
<dc:date>2024-09-04</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Short-Term Effects of Lower Air Temperature and Cold Spells on Myocardial Infarction Hospitalizations in Sweden</dc:title>
<dc:identifier>pmid:39230547</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.07.006</dc:identifier>
</item>
<item>
<title>Bridging Atrial and Ventricular Failure Through Biomarkers</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39230546/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240904161121&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 22:S0735-1097(24)08117-8. doi: 10.1016/j.jacc.2024.08.005. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39230546/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240904161121&v=2.18.0.post9+e462414">39230546</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.005>10.1016/j.jacc.2024.08.005</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39230546</guid>
<pubDate>Wed, 04 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Alberto Aimo</dc:creator>
<dc:creator>Giorgia Panichella</dc:creator>
<dc:creator>Giuseppe Vergaro</dc:creator>
<dc:creator>Antoni Bayes-Genis</dc:creator>
<dc:creator>Michele Emdin</dc:creator>
<dc:date>2024-09-04</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Bridging Atrial and Ventricular Failure Through Biomarkers</dc:title>
<dc:identifier>pmid:39230546</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.005</dc:identifier>
</item>
<item>
<title>ApoA-I Infusions and Burden of Ischemic Events After Acute Myocardial Infarction: Insights From the AEGIS-II Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39230545/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240904161121&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In this prespecified exploratory analysis of the AEGIS-II trial, 4 weekly infusions of CSL112 among high-risk patients after AMI significantly reduced the total burden of nonfatal ischemic events and CV death at 180 and 365 days compared with placebo. (AEGIS-II [Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome]; NCT03473223).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 20:S0735-1097(24)08038-0. doi: 10.1016/j.jacc.2024.08.001. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Following an acute myocardial infarction (AMI), patients remain at risk for subsequent cardiovascular (CV) events. In the AEGIS-II trial, CSL112, a human apolipoprotein A-I derived from plasma that enhances cholesterol efflux, did not significantly reduce the first occurrence of CV death, myocardial infarction (MI), or stroke through 90 days compared with placebo. However, an analysis involving only the first event may not capture the totality of the clinical impact of an intervention because patients may experience multiple events.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This prespecified exploratory analysis examines the effect of CSL112 on total burden of nonfatal ischemic events (ie, recurrent MI and stroke) and CV death.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A total of 18,219 patients with AMI, multivessel coronary artery disease, and additional CV risk factors were randomized to either 4 weekly infusions of 6 g CSL112 (n = 9,112) or matching placebo (n = 9,107). A negative binomial regression model was applied to estimate the effect of CSL112 compared with placebo on the rate ratio (RR) of ischemic events.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: For CV death, MI, and stroke, there were numerically fewer total events at 90 days (503 vs 545 events; rate ratio [RR]: 0.88; 95% CI: 0.76-1.03, P = 0.11), and nominally significantly fewer total events at 180 days (745 vs 821 events, RR: 0.87; 95% CI: 0.77-0.99; P = 0.04) and 365 days (1,120 vs 1,211 events; RR 0.89; 95% CI: 0.80-0.99; P = 0.04). Subsequent events constituted 13% of events at 90 days, 17% at 180 days, and 22% at 1 year. Similar findings were seen with the total occurrence of nonfatal MI and CV death. When type II MIs, unlikely to be modified by enhancing cholesterol efflux, were excluded, there were nominally significant reductions in the total occurrence of nonfatal MI (excluding type 2) and CV death at all timepoints (90 days: RR: 0.81; 95% CI: 0.68-0.97; P = 0.02; 180 days: RR: 0.82; 95% CI: 0.71-0.95; P &lt; 0.01; 365 days: RR: 0.86; 95% CI: 0.76-0.98; P = 0.02).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In this prespecified exploratory analysis of the AEGIS-II trial, 4 weekly infusions of CSL112 among high-risk patients after AMI significantly reduced the total burden of nonfatal ischemic events and CV death at 180 and 365 days compared with placebo. (AEGIS-II [Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome]; NCT03473223).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39230545/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240904161121&v=2.18.0.post9+e462414">39230545</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.001>10.1016/j.jacc.2024.08.001</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39230545</guid>
<pubDate>Wed, 04 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>C Michael Gibson</dc:creator>
<dc:creator>Gerald Chi</dc:creator>
<dc:creator>Danielle Duffy</dc:creator>
<dc:creator>M Cecilia Bahit</dc:creator>
<dc:creator>Harvey White</dc:creator>
<dc:creator>Serge Korjian</dc:creator>
<dc:creator>John H Alexander</dc:creator>
<dc:creator>A Michael Lincoff</dc:creator>
<dc:creator>Gaya Anschuetz</dc:creator>
<dc:creator>Ihab G Girgis</dc:creator>
<dc:creator>Jose C Nicolau</dc:creator>
<dc:creator>Renato D Lopes</dc:creator>
<dc:creator>Jan H Cornel</dc:creator>
<dc:creator>Kevin R Bainey</dc:creator>
<dc:creator>Peter Libby</dc:creator>
<dc:creator>Frank M Sacks</dc:creator>
<dc:creator>Paul M Ridker</dc:creator>
<dc:creator>Shaun G Goodman</dc:creator>
<dc:creator>Kenneth W Mahaffey</dc:creator>
<dc:creator>Stephen J Nicholls</dc:creator>
<dc:creator>Stuart J Pocock</dc:creator>
<dc:creator>Roxana Mehran</dc:creator>
<dc:creator>Robert A Harrington</dc:creator>
<dc:creator>AEGIS-II Committees and Investigators</dc:creator>
<dc:date>2024-09-04</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>ApoA-I Infusions and Burden of Ischemic Events After Acute Myocardial Infarction: Insights From the AEGIS-II Trial</dc:title>
<dc:identifier>pmid:39230545</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.001</dc:identifier>
</item>
<item>
<title>Effect of Screening for Undiagnosed Atrial Fibrillation on Stroke Prevention</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39230544/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240904161121&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In this trial, there was no evidence that screening for AF using a 14-day continuous electrocardiographic monitor in people ≥70 years of age seen in primary care practice reduces stroke hospitalizations. Event rates were low, however, and the trial did not enroll the planned sample size.(Reducing Stroke by Screening for Undiagnosed Atrial Fibrillation in Elderly Individuals [GUARD-AF]; NCT04126486).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 29:S0735-1097(24)08174-9. doi: 10.1016/j.jacc.2024.08.019. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Atrial fibrillation (AF) often remains undiagnosed, and it independently raises the risk of ischemic stroke, which is largely reversible by oral anticoagulation. Although randomized trials using longer term screening approaches increase identification of AF, no studies have established that AF screening lowers stroke rates.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: To address this knowledge gap, the GUARD-AF (Reducing Stroke by Screening for Undiagnosed Atrial Fibrillation in Elderly Individuals) trial screened participants in primary care practices using a 14-day continuous electrocardiographic monitor to determine whether screening for AF coupled with physician/patient decision-making to use oral anticoagulation reduces stroke and provides a net clinical benefit compared with usual care.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: GUARD-AF was a prospective, parallel-group, randomized controlled trial designed to test whether screening for AF in people aged ≥70 years using a 14-day single-lead continuous electrocardiographic patch monitor could identify patients with undiagnosed AF and reduce stroke. Participants were randomized 1:1 to screening or usual care. The primary efficacy and safety outcomes were hospitalization due to all-cause stroke and bleeding, respectively. Analyses used the intention-to-treat population.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Enrollment began on December 17, 2019, and involved 149 primary care sites across the United States. The COVID-19 pandemic led to premature termination of enrollment, with 11,905 participants in the intention-to-treat population. Median follow-up was 15.3 months (Q1-Q3: 13.8-17.6 months). Median age was 75 years (Q1-Q3: 72-79 years), and 56.6% were female. The risk of stroke in the screening group was 0.7% vs 0.6% in the usual care group (HR: 1.10; 95% CI: 0.69-1.75). The risk of bleeding was 1.0% in the screening group vs 1.1% in the usual care group (HR: 0.87; 95% CI: 0.60-1.26). Diagnosis of AF was 5% in the screening group and 3.3% in the usual care group, and initiation of oral anticoagulation after randomization was 4.2% and 2.8%, respectively.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In this trial, there was no evidence that screening for AF using a 14-day continuous electrocardiographic monitor in people ≥70 years of age seen in primary care practice reduces stroke hospitalizations. Event rates were low, however, and the trial did not enroll the planned sample size.(Reducing Stroke by Screening for Undiagnosed Atrial Fibrillation in Elderly Individuals [GUARD-AF]; NCT04126486).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39230544/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240904161121&v=2.18.0.post9+e462414">39230544</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.019>10.1016/j.jacc.2024.08.019</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39230544</guid>
<pubDate>Wed, 04 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Renato D Lopes</dc:creator>
<dc:creator>Steven J Atlas</dc:creator>
<dc:creator>Alan S Go</dc:creator>
<dc:creator>Steven A Lubitz</dc:creator>
<dc:creator>David D McManus</dc:creator>
<dc:creator>Rowena J Dolor</dc:creator>
<dc:creator>Ranee Chatterjee</dc:creator>
<dc:creator>Michael B Rothberg</dc:creator>
<dc:creator>David R Rushlow</dc:creator>
<dc:creator>Lori A Crosson</dc:creator>
<dc:creator>Ronald S Aronson</dc:creator>
<dc:creator>Michael Patlakh</dc:creator>
<dc:creator>Dianne Gallup</dc:creator>
<dc:creator>Donna J Mills</dc:creator>
<dc:creator>Emily C O'Brien</dc:creator>
<dc:creator>Daniel E Singer</dc:creator>
<dc:date>2024-09-04</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Effect of Screening for Undiagnosed Atrial Fibrillation on Stroke Prevention</dc:title>
<dc:identifier>pmid:39230544</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.019</dc:identifier>
</item>
<item>
<title>Heart Failure Risk Assessment Using Biomarkers in Patients With Atrial Fibrillation: Analysis From COMBINE-AF</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39230543/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240904161121&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: NT-proBNP, hs-cTnT, and GDF-15 contributed significantly and independently to the risk stratification for HF endpoints in patients with AF, with hs-cTnT being as important as NT-proBNP for HF risk stratification. Our findings support a possible future use of these biomarkers to distinguish patients with AF at low or high risk for HF.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 19:S0735-1097(24)07965-8. doi: 10.1016/j.jacc.2024.07.023. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Heart failure (HF) is common among patients with atrial fibrillation (AF), and accurate risk assessment is clinically important.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The goal of this study was to investigate the incremental prognostic performance of N-terminal pro-B-type natriuretic peptide (NT-proBNP), high-sensitivity cardiac troponin T (hs-cTnT), and growth differentiation factor (GDF)-15 for HF risk stratification in patients with AF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Individual patient data from 3 large randomized trials comparing direct oral anticoagulants (DOACs) with warfarin (ARISTOTLE [Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation], ENGAGE AF-TIMI 48 [Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48], and RE-LY [Randomized Evaluation of Long-Term Anticoagulation Therapy]) from the COMBINE-AF (A Collaboration Between Multiple Institutions to Better Investigate Non-Vitamin K Antagonist Oral Anticoagulant Use in Atrial Fibrillation) cohort were pooled; all patients with available biomarkers at baseline were included. The composite endpoint was hospitalization for HF (HHF) or cardiovascular death (CVD), and secondary endpoints were HHF and HF-related death. Cox regression was used, adjusting for clinical factors, and interbiomarker correlation was addressed using weighted quantile sum regression analysis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In 32,041 patients, higher biomarker values were associated with a graded increase in absolute risk for CVD/HHF, HHF, and HF-related death. Adjusting for clinical variables and all biomarkers, NT-proBNP (HR per 1 SD: 1.68; 95% CI: 1.59-1.77), hs-cTnT (HR: 1.39; 95% CI: 1.33-1.44), and GDF-15 (HR: 1.20; 95% CI: 1.15-1.25) were significantly associated with CVD/HHF. The discrimination of the clinical model improved significantly upon addition of the biomarkers (c-index: 0.70 [95% CI: 0.69-0.71] to 0.77 [95% CI: 0.76-0.78]; likelihood ratio test, P &lt; 0.001). Using weighted quantile sum regression analysis, the contribution to risk assessment was similar for NT-proBNP and hs-cTnT for CVD/HHF (38% and 41%, respectively); GDF-15 provided a statistically significant but lesser contribution to risk assessment. Results were similar for HHF and HF-related death, individually, and across key subgroups of patients based on history of HF, AF pattern, and reduced or preserved left ventricular ejection fraction.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: NT-proBNP, hs-cTnT, and GDF-15 contributed significantly and independently to the risk stratification for HF endpoints in patients with AF, with hs-cTnT being as important as NT-proBNP for HF risk stratification. Our findings support a possible future use of these biomarkers to distinguish patients with AF at low or high risk for HF.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39230543/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240904161121&v=2.18.0.post9+e462414">39230543</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.07.023>10.1016/j.jacc.2024.07.023</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39230543</guid>
<pubDate>Wed, 04 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Paul M Haller</dc:creator>
<dc:creator>Petr Jarolim</dc:creator>
<dc:creator>Michael G Palazzolo</dc:creator>
<dc:creator>Andrea Bellavia</dc:creator>
<dc:creator>Elliott M Antman</dc:creator>
<dc:creator>John Eikelboom</dc:creator>
<dc:creator>Christopher B Granger</dc:creator>
<dc:creator>Josephine Harrington</dc:creator>
<dc:creator>Jeff S Healey</dc:creator>
<dc:creator>Ziad Hijazi</dc:creator>
<dc:creator>Manesh R Patel</dc:creator>
<dc:creator>Siddharth M Patel</dc:creator>
<dc:creator>Christian T Ruff</dc:creator>
<dc:creator>Lars Wallentin</dc:creator>
<dc:creator>Eugene Braunwald</dc:creator>
<dc:creator>Robert P Giugliano</dc:creator>
<dc:creator>David A Morrow</dc:creator>
<dc:date>2024-09-04</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Heart Failure Risk Assessment Using Biomarkers in Patients With Atrial Fibrillation: Analysis From COMBINE-AF</dc:title>
<dc:identifier>pmid:39230543</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.07.023</dc:identifier>
</item>
<item>
<title>Balancing the Climate Equation: The Unseen Cardiovascular Threat of Cold Spells in a Warming World</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39230542/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240904161121&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 13:S0735-1097(24)07958-0. doi: 10.1016/j.jacc.2024.07.017. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39230542/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240904161121&v=2.18.0.post9+e462414">39230542</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.07.017>10.1016/j.jacc.2024.07.017</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39230542</guid>
<pubDate>Wed, 04 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Kai Chen</dc:creator>
<dc:creator>Khurram Nasir</dc:creator>
<dc:date>2024-09-04</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Balancing the Climate Equation: The Unseen Cardiovascular Threat of Cold Spells in a Warming World</dc:title>
<dc:identifier>pmid:39230542</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.07.017</dc:identifier>
</item>
<item>
<title>Crotonylation of NAE1 Modulates Cardiac Hypertrophy via Gelsolin Neddylation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39229723/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240904161121&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Our findings provide new insights into the previously unrecognized role of crotonylation on nonhistone proteins during cardiac hypertrophy. We found that K238 crotonylation of NAE1 plays an essential role in mediating cardiac hypertrophy through GSN neddylation, which provides potential novel therapeutic targets for pathological hypertrophy and cardiac remodeling.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Sep 4. doi: 10.1161/CIRCRESAHA.124.324733. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Cardiac hypertrophy and its associated remodeling are among the leading causes of heart failure. Lysine crotonylation is a recently discovered posttranslational modification whose role in cardiac hypertrophy remains largely unknown. NAE1 (NEDD8-activating enzyme E1 regulatory subunit) is mainly involved in the neddylation modification of protein targets. However, the function of crotonylated NAE1 has not been defined. This study aims to elucidate the effects and mechanisms of NAE1 crotonylation on cardiac hypertrophy.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Crotonylation levels were detected in both human and mouse subjects with cardiac hypertrophy through immunoprecipitation and Western blot assays. TMT-labeled quantitative lysine crotonylome analysis was performed to identify the crotonylated proteins in a mouse cardiac hypertrophic model induced by transverse aortic constriction. We generated NAE1 knock-in mice carrying a crotonylation-defective lysine to arginine K238R (lysine to arginine mutation at site 238) mutation (NAE1 K238R) and NAE1 knock-in mice expressing a crotonylation-mimicking lysine to glutamine K238Q (lysine to glutamine mutation at site 238) mutation (NAE1 K238Q) to assess the functional role of crotonylation of NAE1 at K238 in pathological cardiac hypertrophy. Furthermore, we combined coimmunoprecipitation, mass spectrometry, and dot blot analysis that was followed by multiple molecular biological methodologies to identify the target GSN (gelsolin) and corresponding molecular events contributing to the function of NAE1 K238 crotonylation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The crotonylation level of NAE1 was increased in mice and patients with cardiac hypertrophy. Quantitative crotonylomics analysis revealed that K238 was the main crotonylation site of NAE1. Loss of K238 crotonylation in NAE1 K238R knock-in mice attenuated cardiac hypertrophy and restored the heart function, while hypercrotonylation mimic in NAE1 K238Q knock-in mice significantly enhanced transverse aortic constriction-induced pathological hypertrophic response, leading to impaired cardiac structure and function. The recombinant adenoviral vector carrying NAE1 K238R mutant attenuated, while the K238Q mutant aggravated Ang II (angiotensin II)-induced hypertrophy. Mechanistically, we identified GSN as a direct target of NAE1. K238 crotonylation of NAE1 promoted GSN neddylation and, thus, enhanced its protein stability and expression. NAE1 crotonylation-dependent increase of GSN promoted actin-severing activity, which resulted in adverse cytoskeletal remodeling and progression of pathological hypertrophy.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our findings provide new insights into the previously unrecognized role of crotonylation on nonhistone proteins during cardiac hypertrophy. We found that K238 crotonylation of NAE1 plays an essential role in mediating cardiac hypertrophy through GSN neddylation, which provides potential novel therapeutic targets for pathological hypertrophy and cardiac remodeling.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39229723/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240904161121&v=2.18.0.post9+e462414">39229723</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.324733>10.1161/CIRCRESAHA.124.324733</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39229723</guid>
<pubDate>Wed, 04 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Jie Ju</dc:creator>
<dc:creator>Kai Wang</dc:creator>
<dc:creator>Fang Liu</dc:creator>
<dc:creator>Cui-Yun Liu</dc:creator>
<dc:creator>Yun-Hong Wang</dc:creator>
<dc:creator>Shao-Chong Wang</dc:creator>
<dc:creator>Lu-Yu Zhou</dc:creator>
<dc:creator>Xin-Min Li</dc:creator>
<dc:creator>Yu-Qin Wang</dc:creator>
<dc:creator>Xin-Zhe Chen</dc:creator>
<dc:creator>Rui-Feng Li</dc:creator>
<dc:creator>Shi-Jun Xu</dc:creator>
<dc:creator>Chen Chen</dc:creator>
<dc:creator>Mei-Hua Zhang</dc:creator>
<dc:creator>Su-Min Yang</dc:creator>
<dc:creator>Jin-Wei Tian</dc:creator>
<dc:creator>Kun Wang</dc:creator>
<dc:date>2024-09-04</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Crotonylation of NAE1 Modulates Cardiac Hypertrophy via Gelsolin Neddylation</dc:title>
<dc:identifier>pmid:39229723</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.324733</dc:identifier>
</item>
<item>
<title>Risk of Stroke or Systemic Embolism According to Baseline Frequency and Duration of Subclinical Atrial Fibrillation: Insights From the ARTESiA Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39229707/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240904161121&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In ARTESiA, baseline SCAF frequency and longest episode duration were not associated with risk of stroke or systemic embolism and did not modify the effect of apixaban on reduction of stroke or systemic embolism.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Sep 4. doi: 10.1161/CIRCULATIONAHA.124.069903. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: In the ARTESiA trial (Apixaban for the Reduction of Thromboembolism in Patients With Device-Detected Subclinical Atrial Fibrillation), apixaban, compared with aspirin, reduced stroke or systemic embolism in patients with device-detected subclinical atrial fibrillation (SCAF). Clinical guidelines recommend considering SCAF episode duration when deciding whether to prescribe oral anticoagulation for this population.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We performed a retrospective cohort study in ARTESiA. Using Cox regression adjusted for CHA<sub>2</sub>DS<sub>2</sub>-VASc score and treatment allocation (apixaban or aspirin), we assessed frequency of SCAF episodes and duration of the longest SCAF episode in the 6 months before randomization as predictors of stroke risk and of apixaban treatment effect.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 3986 patients with complete baseline SCAF data, 703 (17.6%) had no SCAF episode ≥6 minutes in the 6 months before enrollment. Among 3283 patients (82.4%) with ≥1 episode of SCAF ≥6 minutes in the 6 months before enrollment, 2542 (77.4%) had up to 5 episodes, and 741 (22.6%) had ≥6 episodes. The longest episode lasted &lt;1 hour in 1030 patients (31.4%), 1 to &lt;6 hours in 1421 patients (43.3%), and >;6 hours in 832 patients (25.3%). Higher baseline SCAF frequency was not associated with increased risk of stroke or systemic embolism: 1.1% for 1 to 5 episodes versus 1.2%/patient-year for ≥6 episodes (adjusted hazard ratio, 0.89 [95% CI, 0.59-1.34]). In an exploratory analysis, patients with previous SCAF but no episode ≥6 minutes in the 6 months before enrollment had a lower risk of stroke or systemic embolism than patients with at least one episode during that period (0.5% versus 1.1%/patient-year; adjusted hazard ratio, 0.48 [95% CI, 0.27-0.85]). The frequency of SCAF did not modify the reduction in stroke or systemic embolism with apixaban (<i>P</i><sub>interaction</sub>=0.1). The duration of the longest SCAF episode in the 6 months before enrollment was not associated with the risk of stroke or systemic embolism during follow-up (&lt;1 hour: 1.0%/patient-year [reference]; 1-6 hours: 1.2%/patient-year [adjusted hazard ratio, 1.27 (95% CI, 0.85-1.90)]; >;6 hours: 1.0%/patient-year [adjusted hazard ratio, 1.02 (95% CI, 0.63-1.66)]). SCAF duration did not modify the reduction in stroke or systemic embolism with apixaban (<i>P</i><sub>trend</sub>=0.1).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In ARTESiA, baseline SCAF frequency and longest episode duration were not associated with risk of stroke or systemic embolism and did not modify the effect of apixaban on reduction of stroke or systemic embolism.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01938248.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39229707/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240904161121&v=2.18.0.post9+e462414">39229707</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069903>10.1161/CIRCULATIONAHA.124.069903</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39229707</guid>
<pubDate>Wed, 04 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>William F McIntyre</dc:creator>
<dc:creator>Alexander P Benz</dc:creator>
<dc:creator>Jeff S Healey</dc:creator>
<dc:creator>Stuart J Connolly</dc:creator>
<dc:creator>Mu Yang</dc:creator>
<dc:creator>Shun Fu Lee</dc:creator>
<dc:creator>Thalia S Field</dc:creator>
<dc:creator>Marco Alings</dc:creator>
<dc:creator>J Benezet-Mazuecos</dc:creator>
<dc:creator>Giuseppe Boriani</dc:creator>
<dc:creator>J Cosedis Nielsen</dc:creator>
<dc:creator>Michael R Gold</dc:creator>
<dc:creator>Francesco Pergolini</dc:creator>
<dc:creator>Taya V Glotzer</dc:creator>
<dc:creator>Christopher B Granger</dc:creator>
<dc:creator>Renato D Lopes</dc:creator>
<dc:date>2024-09-04</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Risk of Stroke or Systemic Embolism According to Baseline Frequency and Duration of Subclinical Atrial Fibrillation: Insights From the ARTESiA Trial</dc:title>
<dc:identifier>pmid:39229707</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069903</dc:identifier>
</item>
<item>
<title>Efficacy and Safety of Catheter-Based Radiofrequency Renal Denervation in Chinese Patients With Uncontrolled Hypertension: The Randomized, Sham-Controlled, Multi-Center Iberis-HTN Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39229700/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240904161121&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In this trial of Chinese patients with uncontrolled hypertension on a standardized triple pharmacotherapy, RDN was safe and reduced ambulatory and office BP at 6 months compared with sham.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Sep 4. doi: 10.1161/CIRCULATIONAHA.124.069215. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Renal denervation (RDN) can lower blood pressure (BP) in patients with hypertension in both the presence and absence of medication. This is the first sham-controlled trial investigating the safety and efficacy of RDN in China.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This prospective, multicenter, randomized, patient- and outcome-assessor-blinded, sham-controlled trial investigated radiofrequency RDN in patients with hypertension on standardized triple antihypertensive therapy. Eligible patients were randomized 1:1 to undergo RDN using a multi-electrode radiofrequency catheter (Iberis; AngioCare, Shanghai, China) or a sham procedure. The primary efficacy outcome was the between-group difference in baseline-adjusted change in mean 24-hour ambulatory systolic BP from randomization to 6 months.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 217 randomized patients (mean age, 45.3±10.2 years; 21% female), 107 were randomized to RDN and 110 were randomized to sham control. At 6 months, there was a greater reduction in 24-hour systolic BP in the RDN (-13.0±12.1 mm Hg) compared with the sham control group (-3.0±13.0 mm Hg; baseline-adjusted between-group difference, -9.4 mm Hg [95% CI, -12.8 to -5.9]; <i>P</i>&lt;0.001). Compared with sham, 24-hour diastolic BP was lowered by -5.0 mm Hg ([95% CI, -7.5 to -2.4]; <i>P</i>&lt;0.001) 6 months after RDN, and office systolic and diastolic BP was lowered by -6.4 mm Hg ([95% CI, -10.5 to -2.3]; <i>P</i>=0.003) and -5.1 mm Hg ([95% CI, -8.2 to -2.0]; <i>P</i>=0.001), respectively. One patient in the RDN group experienced an access site complication (hematoma), which resolved without sequelae. No other major device- or procedure-related safety events occurred through follow-up.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In this trial of Chinese patients with uncontrolled hypertension on a standardized triple pharmacotherapy, RDN was safe and reduced ambulatory and office BP at 6 months compared with sham.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">REGISTRATION: URL: https://clinicaltrials.gov; Unique identifier: NCT02901704.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39229700/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240904161121&v=2.18.0.post9+e462414">39229700</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069215>10.1161/CIRCULATIONAHA.124.069215</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39229700</guid>
<pubDate>Wed, 04 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Xiongjing Jiang</dc:creator>
<dc:creator>Felix Mahfoud</dc:creator>
<dc:creator>Wei Li</dc:creator>
<dc:creator>Hui Dong</dc:creator>
<dc:creator>Jing Yu</dc:creator>
<dc:creator>Shuhua Yu</dc:creator>
<dc:creator>Xiaoping Chen</dc:creator>
<dc:creator>Peijian Wang</dc:creator>
<dc:creator>Zhiqiang Li</dc:creator>
<dc:creator>Lucas Lauder</dc:creator>
<dc:creator>Zhifang Wang</dc:creator>
<dc:creator>Zheng Ji</dc:creator>
<dc:creator>Yifei Dong</dc:creator>
<dc:creator>Bing Han</dc:creator>
<dc:creator>Zhiming Zhu</dc:creator>
<dc:creator>Yulin Chen</dc:creator>
<dc:creator>Jianzhong Xu</dc:creator>
<dc:creator>Xingsheng Zhao</dc:creator>
<dc:creator>Weidong Fan</dc:creator>
<dc:creator>Wen Xie</dc:creator>
<dc:creator>Brad Hubbard</dc:creator>
<dc:creator>Xi Hu</dc:creator>
<dc:creator>Kazuomi Kario</dc:creator>
<dc:creator>Runlin Gao</dc:creator>
<dc:date>2024-09-04</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Efficacy and Safety of Catheter-Based Radiofrequency Renal Denervation in Chinese Patients With Uncontrolled Hypertension: The Randomized, Sham-Controlled, Multi-Center Iberis-HTN Trial</dc:title>
<dc:identifier>pmid:39229700</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069215</dc:identifier>
</item>
<item>
<title>Sinus sequestration due to transcatheter heart valve endothelialization after transcatheter aortic valve replacement</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39229672/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240904161121&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Sep 4:ehae606. doi: 10.1093/eurheartj/ehae606. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39229672/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240904161121&v=2.18.0.post9+e462414">39229672</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae606>10.1093/eurheartj/ehae606</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39229672</guid>
<pubDate>Wed, 04 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Masatoshi Sato</dc:creator>
<dc:creator>Nobuhiro Yoshijima</dc:creator>
<dc:creator>Fumiaki Yashima</dc:creator>
<dc:date>2024-09-04</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Sinus sequestration due to transcatheter heart valve endothelialization after transcatheter aortic valve replacement</dc:title>
<dc:identifier>pmid:39229672</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae606</dc:identifier>
</item>
<item>
<title>Pre-existing maternal cardiovascular disease and the risk of offspring cardiovascular disease from infancy to early adulthood</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39228375/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240904161121&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Maternal CVD was associated with an increased risk of CVD in offspring during childhood and young adulthood. Paternal comparison suggests that genetic or shared familial factors may not fully explain this association.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Sep 4:ehae547. doi: 10.1093/eurheartj/ehae547. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: A variety of maternal heart conditions are associated with abnormal placentation and reduced foetal growth. However, their impact on offspring's long-term cardiovascular health is poorly studied. This study aims to investigate the association between intrauterine exposure to pre-existing maternal cardiovascular disease (CVD) and offspring CVD occurring from infancy to early adulthood, using paternal CVD as a negative control.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This nationwide cohort study used register data of live singletons without major malformations or congenital heart disease born between 1992 and 2019 in Sweden. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using Cox proportional hazards models, adjusted for essential maternal characteristics. Paternal CVD served as a negative control for assessment of unmeasured genetic and environmental confounding.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of the 2 597 786 offspring analysed (49.1% female), 26 471 (1.0%) were born to mothers with pre-existing CVD. During a median follow-up of 14 years (range 1-29 years), 17 382 offspring were diagnosed with CVD. Offspring of mothers with CVD had 2.09 times higher adjusted HR of CVD (95% CI 1.83, 2.39) compared with offspring of mothers without CVD. Compared with maternal CVD, paternal CVD showed an association of smaller magnitude (HR 1.49, 95% CI 1.32, 1.68). Increased hazards of offspring CVD were also found when stratifying maternal CVD into maternal arrhythmia (HR 2.94, 95% CI 2.41, 3.58), vascular (HR 1.59, 95% CI 1.21, 2.10), and structural heart diseases (HR 1.48, 95% CI 1.08, 2.02).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Maternal CVD was associated with an increased risk of CVD in offspring during childhood and young adulthood. Paternal comparison suggests that genetic or shared familial factors may not fully explain this association.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39228375/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240904161121&v=2.18.0.post9+e462414">39228375</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae547>10.1093/eurheartj/ehae547</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39228375</guid>
<pubDate>Wed, 04 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Muhammad Zakir Hossin</dc:creator>
<dc:creator>Kalliopi Kazamia</dc:creator>
<dc:creator>Jonas Faxén</dc:creator>
<dc:creator>André Rudolph</dc:creator>
<dc:creator>Kari Johansson</dc:creator>
<dc:creator>Anna Sandström</dc:creator>
<dc:creator>Neda Razaz</dc:creator>
<dc:date>2024-09-04</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Pre-existing maternal cardiovascular disease and the risk of offspring cardiovascular disease from infancy to early adulthood</dc:title>
<dc:identifier>pmid:39228375</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae547</dc:identifier>
</item>
<item>
<title>Vulnerable plaque and major adverse cardiovascular events: anatomy of a failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39228369/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240904161121&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Sep 4:ehae553. doi: 10.1093/eurheartj/ehae553. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39228369/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240904161121&v=2.18.0.post9+e462414">39228369</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae553>10.1093/eurheartj/ehae553</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39228369</guid>
<pubDate>Wed, 04 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>C Noel Bairey Merz</dc:creator>
<dc:date>2024-09-04</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Vulnerable plaque and major adverse cardiovascular events: anatomy of a failure</dc:title>
<dc:identifier>pmid:39228369</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae553</dc:identifier>
</item>
<item>
<title>Weekly Journal Scan: SELECT renoprotective effects of semaglutide in non-diabetic, obese patients with cardiovascular disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39228366/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240904161121&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Sep 4:ehae567. doi: 10.1093/eurheartj/ehae567. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39228366/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240904161121&v=2.18.0.post9+e462414">39228366</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae567>10.1093/eurheartj/ehae567</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39228366</guid>
<pubDate>Wed, 04 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Rocco Vergallo</dc:creator>
<dc:creator>Massimo Volpe</dc:creator>
<dc:date>2024-09-04</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Weekly Journal Scan: SELECT renoprotective effects of semaglutide in non-diabetic, obese patients with cardiovascular disease</dc:title>
<dc:identifier>pmid:39228366</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae567</dc:identifier>
</item>
<item>
<title>Late gadolinium enhancement and anomalous coronary aortic origin in a large paediatric cohort</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39228280/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240904161121&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Sep 4:ehae545. doi: 10.1093/eurheartj/ehae545. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39228280/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240904161121&v=2.18.0.post9+e462414">39228280</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae545>10.1093/eurheartj/ehae545</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39228280</guid>
<pubDate>Wed, 04 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Shagun Sachdeva</dc:creator>
<dc:creator>Lauren Ferrino</dc:creator>
<dc:creator>Tam T Doan</dc:creator>
<dc:creator>Dana Reaves-O'Neal</dc:creator>
<dc:creator>Stephen Dolgner</dc:creator>
<dc:creator>Alberto Cipriani</dc:creator>
<dc:creator>Cristina Basso</dc:creator>
<dc:creator>Massimo A Padalino</dc:creator>
<dc:creator>Domenico Corrado</dc:creator>
<dc:creator>Prakash Masand</dc:creator>
<dc:creator>Silvana Molossi</dc:creator>
<dc:date>2024-09-04</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Late gadolinium enhancement and anomalous coronary aortic origin in a large paediatric cohort</dc:title>
<dc:identifier>pmid:39228280</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae545</dc:identifier>
</item>
<item>
<title>Weekly Journal Scan: A large Chinese SPRINT supports 'the lower, the better' blood pressure in hypertensive patients at high cardiovascular risk</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39228278/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240904161121&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Sep 4:ehae531. doi: 10.1093/eurheartj/ehae531. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39228278/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240904161121&v=2.18.0.post9+e462414">39228278</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae531>10.1093/eurheartj/ehae531</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39228278</guid>
<pubDate>Wed, 04 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Rocco Vergallo</dc:creator>
<dc:creator>Massimo Volpe</dc:creator>
<dc:date>2024-09-04</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Weekly Journal Scan: A large Chinese SPRINT supports 'the lower, the better' blood pressure in hypertensive patients at high cardiovascular risk</dc:title>
<dc:identifier>pmid:39228278</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae531</dc:identifier>
</item>
<item>
<title>Finding the right needle in the haystack: the real challenge of AF screening</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39227000/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240904161121&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 21:S0735-1097(24)08247-0. doi: 10.1016/j.jacc.2024.08.036. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39227000/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240904161121&v=2.18.0.post9+e462414">39227000</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.036>10.1016/j.jacc.2024.08.036</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39227000</guid>
<pubDate>Tue, 03 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Xiaoxi Yao</dc:creator>
<dc:creator>Peter A Noseworthy</dc:creator>
<dc:date>2024-09-03</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Finding the right needle in the haystack: the real challenge of AF screening</dc:title>
<dc:identifier>pmid:39227000</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.036</dc:identifier>
</item>
<item>
<title>Unveiling the Unseen: Myosin Inhibitors Cause Reverse Remodeling of Left Ventricular Macro and Microstructure by CMR</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39226999/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240904161121&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 22:S0735-1097(24)08252-4. doi: 10.1016/j.jacc.2024.08.040. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39226999/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240904161121&v=2.18.0.post9+e462414">39226999</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.040>10.1016/j.jacc.2024.08.040</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39226999</guid>
<pubDate>Tue, 03 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Carlos E Rochitte</dc:creator>
<dc:creator>Clerio F Azevedo</dc:creator>
<dc:creator>Fabio Fernandes</dc:creator>
<dc:date>2024-09-03</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Unveiling the Unseen: Myosin Inhibitors Cause Reverse Remodeling of Left Ventricular Macro and Microstructure by CMR</dc:title>
<dc:identifier>pmid:39226999</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.040</dc:identifier>
</item>





























</channel>
</rss>